ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (241)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Szafranski, W.
Right arrow Articles by Olsson, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Szafranski, W.
Right arrow Articles by Olsson, H.
Eur Respir J 2003; 21:74-81
Copyright ©ERS Journals Ltd 2003

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

W. Szafranski1, A. Cukier2, A. Ramirez3, G. Menga4, R. Sansores5, S. Nahabedian6, S. Peterson7 and H. Olsson7

1 Dept Lung Diseases, Voivodeship Specialist Hospital, Radom, Poland. 2 Division of Respiratory Diseases, Hospital das Clinicas, University of Sao Paulo, Sao Paulo, Brazil. 3 Hospital de Enfermedades Cardiovasculares y del Tórax, Monterrey, Mexico. 4 Pneumology Dept, Hospital Maria Ferrer, Buenos Aires, Argentina. 5 Dept of Research in Tobacco Smoking and COPD, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico. 6 Hospital Evita Lanus, Buenos Aires, Argentina. 7 AstraZeneca R&D, Lund, Sweden

CORRESPONDENCE: H. Olsson, AstraZeneca R&D Lund, SE-22187, Lund, Sweden. Fax: 46 46336303. E-mail: Hakan.HOL.Olsson@astrazeneca.com

Keywords: budesonide, budesonide/formoterol, chronic obstructive pulmonary disease, exacerbations, formoterol

Received: April 16, 2002
Accepted August 5, 2002

This study was supported by AstraZeneca.

The efficacy and safety of budesonide/formoterol in a single inhaler compared with placebo, budesonide and formoterol were evaluated in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).

In a 12-month, randomised, double-blind, placebo-controlled, parallel-group study in 812 adults (mean age 64 yrs, mean forced expiratory volume in one second (FEV1) 36% predicted normal), patients received two inhalations twice daily of either budesonide/formoterol (Symbicort®) 160/4.5 µg (delivered dose), budesonide 200 µg (metered dose), formoterol 4.5 µg or placebo. Severe exacerbations and FEV1 (primary variables), peak expiratory flow (PEF), COPD symptoms, health-related quality of life (HRQL), mild exacerbations, use of reliever ß2-agonist and safety variables were recorded.

Budesonide/formoterol reduced the mean number of severe exacerbations per patient per year by 24% versus placebo and 23% versus formoterol. FEV1 increased by 15% versus placebo and 9% versus budesonide. Morning PEF improved significantly on day 1 versus placebo and budesonide; after 1 week, morning PEF was improved versus placebo, budesonide and formoterol. Improvements in morning and evening PEF versus comparators were maintained over 12 months. Budesonide/formoterol decreased all symptom scores and use of reliever ß2-agonists significantly versus placebo and budesonide, and improved HRQL versus placebo. All treatments were well tolerated.

These results suggest a role for budesonide/formoterol in the long-term management of moderate-to-severe chronic obstructive pulmonary disease.




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
P. W. Jones
Triple Therapy for Chronic Obstructive Pulmonary Disease: Trials Catching Up with Clinical Practice?
Am. J. Respir. Crit. Care Med., October 15, 2009; 180(8): 689 - 690.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. Welte, M. Miravitlles, P. Hernandez, G. Eriksson, S. Peterson, T. Polanowski, and R. Kessler
Efficacy and Tolerability of Budesonide/Formoterol Added to Tiotropium in Patients with Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., October 15, 2009; 180(8): 741 - 750.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. J. Rodrigo, J. A. Castro-Rodriguez, and V. Plaza
Safety and Efficacy of Combined Long-Acting {beta}-Agonists and Inhaled Corticosteroids vs Long-Acting {beta}-Agonists Monotherapy for Stable COPD: A Systematic Review
Chest, October 1, 2009; 136(4): 1029 - 1038.
[Abstract] [Full Text] [PDF]

Home page
 Ther Adv Respir DisHome page
M. R. Partridge, W. Schuermann, O. Beckman, T. Persson, and T. Polanowski
Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD
Therapeutic Advances in Respiratory Disease, August 1, 2009; 3(4): 147 - 157.
[Abstract] [PDF]

Home page
 Eur Respir JHome page
D. S. Postma and P. Calverley
Inhaled corticosteroids in COPD: a case in favour
Eur. Respir. J., July 1, 2009; 34(1): 10 - 12.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
S. Suissa and P. J. Barnes
Inhaled corticosteroids in COPD: the case against
Eur. Respir. J., July 1, 2009; 34(1): 13 - 16.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
D-W. Perng, C-W. Tao, K-C. Su, C-C. Tsai, L-Y. Liu, and Y-C. Lee
Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD
Eur. Respir. J., April 1, 2009; 33(4): 778 - 784.
[Abstract] [Full Text] [PDF]

Home page
 Ther Adv Respir DisHome page
R. W. Dal Negro, L. Bonadiman, C. Turati, and P. Turco
Clinical and pharmacoeconomic profile of COPD patients with FEV1 50--60% predicted: pilot study on the impact of the extended indication of ICS/LABA
Therapeutic Advances in Respiratory Disease, April 1, 2009; 3(2): 51 - 58.
[Abstract] [PDF]

Home page
 Postgrad. Med. J.Home page
P N Black and C F McDonald
Interventions to reduce the frequency of exacerbations of chronic obstructive pulmonary disease
Postgrad. Med. J., March 1, 2009; 85(1001): 141 - 147.
[Abstract] [Full Text] [PDF]

Home page
 Ther Adv Respir DisHome page
M. Cazzola
From large clinical trials to management of COPD in the real world
Therapeutic Advances in Respiratory Disease, February 1, 2009; 3(1): 39 - 46.
[Abstract] [PDF]

Home page
 JAMAHome page
M. B. Drummond, E. C. Dasenbrook, M. W. Pitz, D. J. Murphy, and E. Fan
Inhaled Corticosteroids in Patients With Stable Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis
JAMA, November 26, 2008; 300(20): 2407 - 2416.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
M Najafzadeh, C A Marra, M Sadatsafavi, S D Aaron, S D Sullivan, K L Vandemheen, P W Jones, and J M Fitzgerald
Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD
Thorax, November 1, 2008; 63(11): 962 - 967.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
A. Tronde, M. Gillen, L. Borgstrom, J. Lotvall, and J. Ankerst
Pharmacokinetics of Budesonide and Formoterol Administered Via 1 Pressurized Metered-Dose Inhaler in Patients With Asthma and COPD
J. Clin. Pharmacol., November 1, 2008; 48(11): 1300 - 1308.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
B. R. Celli, N. E. Thomas, J. A. Anderson, G. T. Ferguson, C. R. Jenkins, P. W. Jones, J. Vestbo, K. Knobil, J. C. Yates, and P. M. A. Calverley
Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease: Results from the TORCH Study
Am. J. Respir. Crit. Care Med., August 15, 2008; 178(4): 332 - 338.
[Abstract] [Full Text] [PDF]

Home page
 Ther Adv Respir DisHome page
J. F. Donohue, N. A. Hanania, C. Fogarty, S. C. Campbell, M. Rinehart, and K. Denis-Mize
Long-term safety of nebulized formoterol: Results of a twelve-month open-label clinical trial
Therapeutic Advances in Respiratory Disease, August 1, 2008; 2(4): 199 - 208.
[Abstract] [PDF]

Home page
 Eur Respir JHome page
O. N. Keene, P. M. A. Calverley, P. W. Jones, J. Vestbo, and J. A. Anderson
Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited
Eur. Respir. J., July 1, 2008; 32(1): 17 - 24.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
B. R. Celli
Update on the Management of COPD
Chest, June 1, 2008; 133(6): 1451 - 1462.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P. Albert and P. M. A. Calverley
Drugs (including oxygen) in severe COPD
Eur. Respir. J., May 1, 2008; 31(5): 1114 - 1124.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
J. A. Falk, O. A. Minai, and Z. Mosenifar
Inhaled and Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, May 1, 2008; 5(4): 506 - 512.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
S. Suissa, P. Ernst, K. L. Vandemheen, and S. D. Aaron
Methodological issues in therapeutic trials of COPD
Eur. Respir. J., May 1, 2008; 31(5): 927 - 933.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. J. Rodrigo, L. J. Nannini, and R. Rodriguez-Roisin
Safety of Long-Acting {beta}-Agonists in Stable COPD: A Systematic Review
Chest, May 1, 2008; 133(5): 1079 - 1087.
[Abstract] [Full Text] [PDF]

Home page
 Ther Adv Respir DisHome page
J.F. Donohue, N.A. Hanania, K.A. Sciarappa, E. Goodwin, D.R. Grogan, R.A. Baumgartner, and J.P. Hanrahan
Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: A one year evaluation of safety and tolerance
Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 37 - 48.
[Abstract] [PDF]

Home page
 ThoraxHome page
M Sridhar, R Taylor, S Dawson, N J Roberts, and M R Partridge
A nurse led intermediate care package in patients who have been hospitalised with an acute exacerbation of chronic obstructive pulmonary disease
Thorax, March 1, 2008; 63(3): 194 - 200.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al.
Outcomes for COPD pharmacological trials: from lung function to biomarkers
Eur. Respir. J., February 1, 2008; 31(2): 416 - 469.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
S D Aaron, D Fergusson, G B Marks, S Suissa, K L Vandemheen, S Doucette, F Maltais, J F Bourbeau, R S Goldstein, M Balter, et al.
Counting, analysing and reporting exacerbations of COPD in randomised controlled trials
Thorax, February 1, 2008; 63(2): 122 - 128.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
P. Jones and T. Higenbottam
Quantifying of Severity of Exacerbations in Chronic Obstructive Pulmonary Disease: Adaptations to the Definition to Allow Quantification
Proceedings of the ATS, December 1, 2007; 4(8): 597 - 601.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
A. Qaseem, V. Snow, P. Shekelle, K. Sherif, T. J. Wilt, S. Weinberger, D. K. Owens, and for the Clinical Efficacy Assessment Subcommittee
Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline from the American College of Physicians
Ann Intern Med, November 6, 2007; 147(9): 633 - 638.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
T. J. Wilt, D. Niewoehner, R. MacDonald, and R. L. Kane
Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline
Ann Intern Med, November 6, 2007; 147(9): 639 - 653.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. Loven, N. Svitacheva, A. Jerre, A. Miller-Larsson, and S. H. Korn
Anti-inflammatory activity of {beta}2-agonists in primary lung epithelial cells is independent of glucocorticoid receptor
Eur. Respir. J., November 1, 2007; 30(5): 848 - 856.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. Bourbeau, G. Ford, H. Zackon, N. Pinsky, J. Lee, and G. Ruberto
Impact on patients' health status following early identification of a COPD exacerbation
Eur. Respir. J., November 1, 2007; 30(5): 907 - 913.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
N. Barnes
Reducing inflammation in COPD: the evidence builds
Thorax, November 1, 2007; 62(11): 927 - 928.
[Full Text] [PDF]

Home page
 ThoraxHome page
J. Bourbeau, P. Christodoulopoulos, F. Maltais, Y. Yamauchi, R. Olivenstein, and Q. Hamid
Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial
Thorax, November 1, 2007; 62(11): 938 - 943.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
S. Suissa, R. McGhan, D. Niewoehner, and B. Make
Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, October 1, 2007; 4(7): 535 - 542.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
K. F. Rabe, S. Hurd, A. Anzueto, P. J. Barnes, S. A. Buist, P. Calverley, Y. Fukuchi, C. Jenkins, R. Rodriguez-Roisin, C. van Weel, et al.
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary
Am. J. Respir. Crit. Care Med., September 15, 2007; 176(6): 532 - 555.
[Abstract] [Full Text] [PDF]

Home page
 ERRHome page
N. Roche
Where current pharmacological therapies fall short in COPD: symptom control is not enough
Eur. Respir. Rev., September 1, 2007; 16(105): 98 - 104.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. Suissa
On the Correct Statistical Analysis of Exacerbation Rates in Clinical Trials
Am. J. Respir. Crit. Care Med., September 1, 2007; 176(5): 522 - 522.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. M. A. Calverley, F. Sanchez-Toril, A. McIvor, P. Teichmann, D. Bredenbroeker, and L. M. Fabbri
Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., July 15, 2007; 176(2): 154 - 161.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. J. Carr, R. S. Goldstein, and D. Brooks
Acute Exacerbations of COPD in Subjects Completing Pulmonary Rehabilitation
Chest, July 1, 2007; 132(1): 127 - 134.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. Kardos, M. Wencker, T. Glaab, and C. Vogelmeier
Avoiding Mistakes in Calculating the Number Needed to Treat in Severe COPD
Am. J. Respir. Crit. Care Med., June 15, 2007; 175(12): 1347b - 1348.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
B. R. Celli and P. J. Barnes
Exacerbations of chronic obstructive pulmonary disease
Eur. Respir. J., June 1, 2007; 29(6): 1224 - 1238.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
C-G. Lofdahl, D. S. Postma, N. B. Pride, J. Boe, and A. Thoren
Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD
Eur. Respir. J., June 1, 2007; 29(6): 1115 - 1119.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
Y. Oba
Cost-Effectiveness of Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease
Mayo Clin. Proc., May 1, 2007; 82(5): 575 - 582.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
G. J. Criner
Optimal Treatment of Chronic Obstructive Pulmonary Disease: The Search for the Magic Combination of Inhaled Bronchodilators and Corticosteroids
Ann Intern Med, April 17, 2007; 146(8): 606 - 608.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
S. D. Aaron, K. L. Vandemheen, D. Fergusson, F. Maltais, J. Bourbeau, R. Goldstein, M. Balter, D. O'Donnell, A. McIvor, S. Sharma, et al.
Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease: A Randomized Trial
Ann Intern Med, April 17, 2007; 146(8): 545 - 555.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. B. Soriano, D. D. Sin, X. Zhang, P. G. Camp, J. A. Anderson, N. R. Anthonisen, A. S. Buist, P. S. Burge, P. M. Calverley, J. E. Connett, et al.
A Pooled Analysis of FEV1 Decline in COPD Patients Randomized to Inhaled Corticosteroids or Placebo
Chest, March 1, 2007; 131(3): 682 - 689.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
V. Soyseth, P. H. Brekke, P. Smith, and T. Omland
Statin use is associated with reduced mortality in COPD
Eur. Respir. J., February 1, 2007; 29(2): 279 - 283.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. E. Niewoehner and T. J. Wilt
Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease: A Status Report
Am. J. Respir. Crit. Care Med., January 15, 2007; 175(2): 103 - 104.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. Kardos, M. Wencker, T. Glaab, and C. Vogelmeier
Impact of Salmeterol/Fluticasone Propionate versus Salmeterol on Exacerbations in Severe Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., January 15, 2007; 175(2): 144 - 149.
[Abstract] [Full Text] [PDF]

Home page
 ERRHome page
D. E. O'Donnell
Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance
Eur. Respir. Rev., December 1, 2006; 15(99): 37 - 41.
[Abstract] [Full Text] [PDF]

Home page
 ERRHome page
R. Rodriguez-Roisin
Impacting patient-centred outcomes in COPD: exacerbations and hospitalisations
Eur. Respir. Rev., December 1, 2006; 15(99): 47 - 51.
[Abstract] [Full Text] [PDF]

Home page
 ERRHome page
M. Decramer
Tiotropium as essential maintenance therapy in COPD
Eur. Respir. Rev., December 1, 2006; 15(99): 51 - 57.
[Abstract] [Full Text] [PDF]

Home page
 ERRHome page
A. Agusti and J. B. Soriano
Dynamic hyperinflation and pulmonary inflammation: a potentially relevant relationship?
Eur. Respir. Rev., December 1, 2006; 15(100): 68 - 71.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P. P. Walker, P. Mitchell, F. Diamantea, C. J. Warburton, and L. Davies
Effect of primary-care spirometry on the diagnosis and management of COPD
Eur. Respir. J., November 1, 2006; 28(5): 945 - 952.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
N. Stenfors
Physician-Diagnosed COPD Global Initiative for Chronic Obstructive Lung Disease Stage IV in Ostersund, Sweden: Patient Characteristics and Estimated Prevalence.
Chest, September 1, 2006; 130(3): 666 - 671.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
D. D. Sin and S. F. P. Man
Pharmacotherapy for Mortality Reduction in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, September 1, 2006; 3(7): 624 - 629.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
R. Kessler, E. Stahl, C. Vogelmeier, J. Haughney, E. Trudeau, C.-G. Lofdahl, and M. R. Partridge
Patient Understanding, Detection, and Experience of COPD Exacerbations: An Observational, Interview-Based Study.
Chest, July 1, 2006; 130(1): 133 - 142.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
P. W. Jones
Health Status: What Does It Mean for Payers and Patients?
Proceedings of the ATS, May 1, 2006; 3(3): 222 - 226.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
J. Vestbo
Clinical Assessment, Staging, and Epidemiology of Chronic Obstructive Pulmonary Disease Exacerbations
Proceedings of the ATS, May 1, 2006; 3(3): 252 - 256.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
P. S. Burge
Prevention of Exacerbations: How Are We Doing and Can We Do Better?
Proceedings of the ATS, May 1, 2006; 3(3): 257 - 261.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
E. F. M. Wouters
Approaches to Improving Health Status in Chronic Obstructive Pulmonary Disease: One or Several?
Proceedings of the ATS, May 1, 2006; 3(3): 262 - 269.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
K. F. Rabe
Improving Dyspnea in Chronic Obstructive Pulmonary Disease: Optimal Treatment Strategies
Proceedings of the ATS, May 1, 2006; 3(3): 270 - 275.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
R. Leigh, M. M. M. Pizzichini, M. M. Morris, F. Maltais, F. E. Hargreave, and E. Pizzichini
Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment
Eur. Respir. J., May 1, 2006; 27(5): 964 - 971.
[Abstract] [Full Text] [PDF]

Home page
 Ann Fam MedHome page
G. Gartlehner, R. A. Hansen, S. S. Carson, and K. N. Lohr
Efficacy and Safety of Inhaled Corticosteroids in Patients With COPD: A Systematic Review and Meta-Analysis of Health Outcomes
Ann. Fam. Med, May 1, 2006; 4(3): 253 - 262.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
S Scott, P Walker, and P M A Calverley
COPD exacerbations {middle dot} 4: Prevention
Thorax, May 1, 2006; 61(5): 440 - 447.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. Suissa
Statistical Treatment of Exacerbations in Therapeutic Trials of Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., April 15, 2006; 173(8): 842 - 846.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P. W. Jones and A. G. N. Agusti
Outcomes and markers in the assessment of chronic obstructive pulmonary disease.
Eur. Respir. J., April 1, 2006; 27(4): 822 - 832.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
N. C. Barnes, Y.-S. Qiu, I. D. Pavord, D. Parker, P. A. Davis, J. Zhu, M. Johnson, N. C. Thomson, P. K. Jeffery, and on behalf of the SCO30005 Study Group
Antiinflammatory Effects of Salmeterol/Fluticasone Propionate in Chronic Obstructive Lung Disease
Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 736 - 743.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. E. O'Donnell
Is Sustained Pharmacologic Lung Volume Reduction Now Possible in COPD?
Chest, March 1, 2006; 129(3): 501 - 503.
[Full Text] [PDF]

Home page
 ThoraxHome page
R A Stockley, N Chopra, L Rice, and on behalf of the SMS40026 Investigator Group
Addition of salmeterol to existing treatment in patients with COPD: a 12 month study
Thorax, February 1, 2006; 61(2): 122 - 128.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
B. R. Celli
Chronic Obstructive Pulmonary Disease: From Unjustified Nihilism to Evidence-based Optimism.
Proceedings of the ATS, January 1, 2006; 3(1): 58 - 65.
[Abstract] [Full Text] [PDF]

Home page
 ERRHome page
M. Soler
Modulation of airway inflammation to prevent exacerbations of COPD
Eur. Respir. Rev., December 1, 2005; 14(95): 78 - 82.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
J A Wedzicha and T A R Seemungal
Inhaled corticosteroids in COPD: a light at the end of the tunnel?
Thorax, December 1, 2005; 60(12): 977 - 978.
[Full Text] [PDF]

Home page
 ThoraxHome page
D D Sin, L Wu, J A Anderson, N R Anthonisen, A S Buist, P S Burge, P M Calverley, J E Connett, B Lindmark, R A Pauwels, et al.
Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease
Thorax, December 1, 2005; 60(12): 992 - 997.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
J. F. Donohue
Combination Therapy for Chronic Obstructive Pulmonary Disease: Clinical Aspects
Proceedings of the ATS, November 1, 2005; 2(4): 272 - 281.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
M. Johnson
Corticosteroids: Potential {beta}2-Agonist and Anticholinergic Interactions in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, November 1, 2005; 2(4): 320 - 325.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. Haughney, M. R. Partridge, C. Vogelmeier, T. Larsson, R. Kessler, E. Stahl, R. Brice, and C-G. Lofdahl
Exacerbations of COPD: quantifying the patient's perspective using discrete choice modelling
Eur. Respir. J., October 1, 2005; 26(4): 623 - 629.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
D. E. Niewoehner, K. Rice, C. Cote, D. Paulson, J. A. D. Cooper Jr., L. Korducki, C. Cassino, and S. Kesten
Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium, a Once-Daily Inhaled Anticholinergic Bronchodilator: A Randomized Trial
Ann Intern Med, September 6, 2005; 143(5): 317 - 326.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P. Calverley, R. Pauwels{dagger}, C-G. Lofdahl, K. Svensson, T. Higenbottam, L-G. Carlsson, and E. Stahl
Relationship between respiratory symptoms and medical treatment in exacerbations of COPD
Eur. Respir. J., September 1, 2005; 26(3): 406 - 413.
[Abstract] [Full Text] [PDF]

Home page
 ERRHome page
P. J. Barnes
New approaches to COPD
Eur. Respir. Rev., September 1, 2005; 14(94): 2 - 11.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. A. van Noord, J-L. Aumann, E. Janssens, J. J. Smeets, J. Verhaert, B. Disse, A. Mueller, and P. J. G. Cornelissen
Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD
Eur. Respir. J., August 1, 2005; 26(2): 214 - 222.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P. J. Barnes and R. A. Stockley
COPD: current therapeutic interventions and future approaches
Eur. Respir. J., June 1, 2005; 25(6): 1084 - 1106.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
E F M Wouters, D S Postma, B Fokkens, W C J Hop, J Prins, A F Kuipers, H R Pasma, C A J Hensing, E C Creutzberg, and for the COSMIC (COPD and Seretide: a Multi-Center
Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial
Thorax, June 1, 2005; 60(6): 480 - 487.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M.-F. Beauchesne, M. Lalande, A. Fillion, and L. Blais
Inhaled corticosteroids and rate of exacerbations in patients with COPD
Ann. Pharmacother., May 1, 2005; 39(5): 973 - 974.
[Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
R. Buhl and S. G. Farmer
Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, April 1, 2005; 2(1): 83 - 93.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
J Vestbo, R Pauwels, J A Anderson, P Jones, P Calverley, and on behalf of the TRISTAN study group
Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease
Thorax, April 1, 2005; 60(4): 301 - 304.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
M Decramer, R Gosselink, M Rutten-Van Molken, J Buffels, O Van Schayck, P-A Gevenois, R Pellegrino, E Derom, and W De Backer
Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004
Thorax, April 1, 2005; 60(4): 335 - 342.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
M Decramer, R Gosselink, P Bartsch, C-G Lofdahl, W Vincken, R Dekhuijzen, J Vestbo, R Pauwels, R Naeije, and T Troosters
Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004
Thorax, April 1, 2005; 60(4): 343 - 349.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
C B Cooper and D P Tashkin
Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease
BMJ, March 19, 2005; 330(7492): 640 - 644.
[Full Text] [PDF]

Home page
 ThoraxHome page
C E Brightling, S McKenna, B Hargadon, S Birring, R Green, R Siva, M Berry, D Parker, W Monteiro, I D Pavord, et al.
Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease
Thorax, March 1, 2005; 60(3): 193 - 198.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P.M.A. Calverley
From the author
Eur. Respir. J., December 1, 2004; 24(6): 1070 - 1071.
[Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
J. F. Donohue and J. A. Ohar
Effects of Corticosteroids on Lung Function in Asthma and Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, November 1, 2004; 1(3): 152 - 160.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
P. M. A. Calverley
Effect of Corticosteroids on Exacerbations of Asthma and Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, November 1, 2004; 1(3): 161 - 166.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
P. W. Jones
Clinical Effects of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, November 1, 2004; 1(3): 167 - 170.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
M. Johnson
Interactions between Corticosteroids and {beta}2-Agonists in Asthma and Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, November 1, 2004; 1(3): 200 - 206.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. A. Mahler, S. Huang, M. Tabrizi, and G. M. Bell
Efficacy and Safety of a Monoclonal Antibody Recognizing Interleukin-8 in COPD: A Pilot Study
Chest, September 1, 2004; 126(3): 926 - 934.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
The TORCH Study Group
The TORCH (TOwards a Revolution in COPD Health) survival study protocol
Eur. Respir. J., August 1, 2004; 24(2): 206 - 210.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
F. A. El-Kassimi and N. A. Hanania
Differentiating Asthma and COPD Patients
Chest, August 1, 2004; 126(2): 653 - 655.
[Full Text] [PDF]

Home page
 ChestHome page
D. W. Mapel
Treatment Implications on Morbidity and Mortality in COPD
Chest, August 1, 2004; 126(2_suppl_1): 150S - 158S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Cazzola and R. Dahl
Inhaled Combination Therapy With Long-Acting {beta}2-Agonists and Corticosteroids in Stable COPD
Chest, July 1, 2004; 126(1): 220 - 237.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the European Respiratory Society.